Endocrinology · Metabolic Research
Cagrilintide
Reference Compound
Cagrilintide is a long-acting analog of amylin (islet amyloid polypeptide) engineered with substitutions that prevent fibrillation and a fatty-acid acylation that mediates albumin binding for a once-weekly half-life. The compound binds amylin receptors (AMY1, AMY2, AMY3) — heterodimers of the calcitonin receptor with receptor activity-modifying proteins — and also the calcitonin receptor.
Latest lot released Oct 7PAP-3711-26
At a Glance
- MW
- ~3800 Da
- Sequence
- Long-acting amylin analog
- Half-life
- ~7–8 days
- Route
- Subcutaneous in research models
- Storage
- −20°C long term; 2–8°C short term (weeks). Protect from light.
Quality Documentation
Lot PAP-CAGRIL-240118-A01 — Reference
Overview
Field of Medicine — Endocrinology · Metabolic Research
Field of Medicine
Endocrinology and Obesity Research — long-acting amylin analog.
Background
Cagrilintide is a synthetic long-acting analog of amylin, a pancreatic peptide co-secreted with insulin. Lipidation extends its half-life to support weekly dosing in research settings, and it is frequently studied in combination with GLP-1 receptor agonists.
Mechanism of Action
Cagrilintide engages amylin and calcitonin receptor complexes in the area postrema and hypothalamus, contributing to satiety signaling, slowed gastric emptying, and reduced postprandial glucagon. The amylin pathway is complementary to incretin signaling, which is why combination research (e.g. with semaglutide) is an active area.
Research Applications
- Appetite-regulation and satiety models.
- Combination pharmacology with incretin agonists.
- Obesity and metabolic-syndrome research.
Reference Compound
Cagrilintide